Antifungal Pharmacokinetics and Pharmacodynamics

被引:85
|
作者
Lepak, Alexander J. [1 ]
Andes, David R. [1 ]
机构
[1] Univ Wisconsin, Madison, WI 53705 USA
来源
关键词
INVASIVE PULMONARY ASPERGILLOSIS; LIPOSOMAL AMPHOTERICIN-B; IN-VITRO MODEL; GUINEA-PIG MODEL; HEMATOGENOUS CANDIDA MENINGOENCEPHALITIS; GALACTOMANNAN ENZYME-IMMUNOASSAY; NEUTROPENIC MURINE MODEL; DOSE-DEPENDENT ACTIVITY; COMBINATION THERAPY; LIPID COMPLEX;
D O I
10.1101/cshperspect.a019653
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Successful treatment of infectious diseases requires choice of the most suitable antimicrobial agent, comprising consideration of drug pharmacokinetics (PK), including penetration into infection site, pathogen susceptibility, optimal route of drug administration, drug dose, frequency of administration, duration of therapy, and drug toxicity. Antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) studies consider these variables and have been useful in drug development, optimizing dosing regimens, determining susceptibility breakpoints, and limiting toxicity of antifungal therapy. Here the concepts of antifungal PK/PD studies are reviewed, with emphasis on methodology and application. The initial sections of this review focus on principles and methodology. Then the pharmacodynamics of each major antifungal drug class (polyenes, flucytosine, azoles, and echinocandins) is discussed. Finally, the review discusses novel areas of pharmacodynamic investigation in the study and application of combination therapy.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and In Vitro Susceptibility Breakpoints
    Sudan, Ajay
    Livermore, Joanne
    Howard, Susan J.
    Al-Nakeeb, Zaid
    Sharp, Andrew
    Goodwin, Joanne
    Gregson, Lea
    Warn, Peter A.
    Felton, Tim W.
    Perfect, John R.
    Harrison, Thomas S.
    Hope, William W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (06) : 2793 - 2800
  • [22] Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis
    Ali A. Alhadab
    Joshua Rhein
    Lillian Tugume
    Abdu Musubire
    Darlisha A. Williams
    Mahsa Abassi
    Melanie R. Nicol
    David B. Meya
    David R. Boulware
    Richard C. Brundage
    Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46 : 565 - 576
  • [23] The correlation between pharmacodynamics and pharmacokinetics: Basics of pharmacokinetics - Pharmacodynamics modeling
    Cawello, W
    Antonucci, T
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (01): : S65 - S69
  • [24] Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review
    Sinnollareddy, Mahipal
    Peake, Sandra L.
    Roberts, Michael S.
    Lipman, Jeffrey
    Roberts, Jason A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2012, 39 (01) : 1 - 10
  • [25] Pharmacokinetics and Pharmacodynamics of Antibacterial and Antifungal Agents in Adult Patients With Thermal Injury: A Review of Current Literature
    Ortwine, Jessica K.
    Pogue, Jason M.
    Faris, Janie
    JOURNAL OF BURN CARE & RESEARCH, 2015, 36 (02): : E72 - E84
  • [26] Variegin: pharmacokinetics and pharmacodynamics
    Shih, N.
    Amran, F.
    Koh, C. Y.
    Chan, M. Y. Y.
    Kini, R. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 5 - 5
  • [27] Pharmacokinetics and Pharmacodynamics of Tedizolid
    Khalid Iqbal
    Aliki Milioudi
    Sebastian Georg Wicha
    Clinical Pharmacokinetics, 2022, 61 : 489 - 503
  • [28] PHARMACOKINETICS AND PHARMACODYNAMICS FOR THE CLINICIAN
    STANSKI, DR
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1991, 38 (04): : R48 - R53
  • [29] PHARMACODYNAMICS AND PHARMACOKINETICS OF GLUCOCORTICOIDS
    OETTEL, M
    MONATSHEFTE FUR VETERINARMEDIZIN, 1984, 39 (24): : 829 - 833
  • [30] PHARMACOKINETICS AND PHARMACODYNAMICS OF DILEVALOL
    TENERO, DM
    BOTTORFF, MB
    GIVEN, BD
    KRAMER, WG
    AFFRIME, MB
    PATRICK, JE
    LALONDE, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (06) : 648 - 656